Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

115

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

May 30, 2025

Study Completion Date

July 31, 2026

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

FPI-2265

Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225

Trial Locations (2)

XCancer Omaha/Urology Cancer Center, Omaha

Excel Diagnostics and Nuclear Oncology Center, Houston